MARKET

OMER

OMER

Omeros
NASDAQ
4.410
-0.090
-2.00%
After Hours: 4.410 0 0.00% 16:27 11/08 EST
OPEN
4.480
PREV CLOSE
4.500
HIGH
4.515
LOW
4.380
VOLUME
179.58K
TURNOVER
--
52 WEEK HIGH
5.68
52 WEEK LOW
1.130
MARKET CAP
255.55M
P/E (TTM)
-1.8803
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at OMER last week (1028-1101)?
Weekly Report · 6d ago
Weekly Report: what happened at OMER last week (1021-1025)?
Weekly Report · 10/28 12:06
Omeros gets FDA rare pediatric disease designation for renal disorder treatment
Seeking Alpha · 10/24 13:13
FDA GRANTS RARE PEDIATRIC DISEASE DESIGNATION TO OMEROS’ MASP-3 INHIBITOR ZALTENIBART FOR TREATMENT OF C3 GLOMERULOPATHY
Reuters · 10/24 12:45
Weekly Report: what happened at OMER last week (1014-1018)?
Weekly Report · 10/21 12:00
Weekly Report: what happened at OMER last week (1007-1011)?
Weekly Report · 10/14 12:40
Weekly Report: what happened at OMER last week (0930-1004)?
Weekly Report · 10/07 12:26
Weekly Report: what happened at OMER last week (0923-0927)?
Weekly Report · 09/30 12:16
More
About OMER
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.

Webull offers Omeros Corp stock information, including NASDAQ: OMER real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OMER stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OMER stock methods without spending real money on the virtual paper trading platform.